ZURZUVAE — Total Revenue
Biogen ZURZUVAE — Total Revenue decreased by 15.7% to $55.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from $27.70M to $55.40M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, higher prescription volumes, or effective pricing strategies for the product, while a decrease may signal competitive pressure, loss of market share, or declining demand.
Detailed definition
This metric represents the total gross revenue generated from the commercial sale of the ZURZUVAE product line. It refle...
Peer comparison
Comparable to product-specific revenue reporting in other biopharmaceutical companies, often benchmarked against therapeutic area peers or new drug launch performance metrics.
biib_segment_zurzuvae_total_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $12.40M | $14.90M | $22.00M | $22.90M | $27.70M | $46.40M | $55.30M | $65.70M | $55.40M |
| QoQ Change | — | — | — | — | — | — | — | +20.2% | +47.7% | +4.1% | +21.0% | +67.5% | +19.2% | +18.8% | -15.7% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | +123.4% | +211.4% | +151.4% | +186.9% | +100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's zurzuvae — total revenue?
- Biogen (BIIB) reported zurzuvae — total revenue of $55.40M in Q1 2026.
- How has Biogen's zurzuvae — total revenue changed year-over-year?
- Biogen's zurzuvae — total revenue increased by 100.0% year-over-year, from $27.70M to $55.40M.
- What does zurzuvae — total revenue mean?
- The total sales revenue earned from the ZURZUVAE product.